ARTICLE | Clinical News
Cannabidivarin: Phase II started
May 18, 2015 7:00 AM UTC
GW began a double-blind, placebo-controlled, U.S. Phase II trial to evaluate twice-daily oral GWP42006 plus antiepileptic drugs in patients with inadequately controlled focal seizures. GW and Otsuka p...